Mergers & Acquisitions ·
Eli Lilly acquires substantially all assets from Sangamo for $50M in cash
SGMOQSangamo Therapeutics, Inc
Sangamo Therapeutics, Inc. completed the sale of substantially all of its assets, including its AAV capsid engineering platform (STAC-BBB), zinc finger protein technology, Modular Integrase genome editing platform, and prion disease program, to Eli Lilly and Company for $50 million in cash plus assumption of specified liabilities. The transaction closed on September 4, 2026, following the company's Chapter 11 bankruptcy filing on June 23, 2026. During the July reporting period, the company incurred $18 million in replacement debtor-in-possession financing obligations and reported a net loss of approximately $11.2 million with ending cash balances of roughly $16.9 million. Sangamo Therapeutics operates in the biotechnology industry, focusing on gene editing and therapeutic development.